Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,051.99 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS)
Today is February 10, 2026. The telehealth landscape stands at a historic inflection point, and no company better embodies this volatility than Hims & Hers Health, Inc. (NYSE: HIMS). After a meteoric... 
Via Finterra
Topics Artificial Intelligence Intellectual Property Lawsuit
News headline image
Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know. ↗
Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗
The stock has climbed in the triple digits over the past three years. 
Via The Motley Fool
FDA "Swift Action" Warning Sends Hims & Hers into a Tailspin ↗
Via Chartmill
News headline image
What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results this Wednesday morning. Here’s what to expect. 
Via StockStory
Topics World Trade
News headline image
Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗
These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Over 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried? ↗
Mounjaro and Zepbound generated a combined $11.7 billion in sales for the company in its most recent quarter. 
Via The Motley Fool
News headline image
The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash
The multi-billion dollar weight-loss drug market experienced a seismic shift this morning as the era of easy-access compounded alternatives faced its most significant legal and regulatory challenge to... 
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Why Eli Lilly Stock Just Popped ↗
Novo Nordisk just did Eli Lilly stock a huge favor. 
Via The Motley Fool
Topics Lawsuit
News headline image
Grounded in Reality or Echoes of '99? Merrill Strategists Say Today’s S&P 500 Is a Different Beast
As the S&P 500 (INDEXSP: .INX) pushes toward the 7,100 mark in early 2026, a growing chorus of investors is nervously glancing back at the ghosts of 1999. With the index having notched double-digit... 
Via MarketMinute
Topics Artificial Intelligence Lawsuit Stocks
News headline image
The GLP-1 Gold Rush Hits a Wall: Hims & Hers Shares Crater After Abrupt Oral Wegovy U-Turn
The meteoric rise of telehealth giant Hims & Hers Health (NYSE: HIMS) faced its most severe reckoning this week, as the company’s stock plummeted to a one-year low following a dramatic withdrawal of... 
Via MarketMinute
Topics Earnings Intellectual Property
News headline image
The GLP-1 Reckoning: Why Hims & Hers (HIMS) Pivoted and Shed 20% of Its Value
On February 9, 2026, the telehealth landscape faces a reckoning. Hims & Hers Health (NYSE: HIMS), a company that once seemed invincible during the weight-loss drug gold rush of 2025, is currently... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments ↗
Eli Lilly shares rise after announcing a $2.4 billion deal to buy Orna Therapeutics, strengthening its push into genetic medicine despite mixed markets. 
Via Benzinga
Monday's pre-market session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
LLY Stock Climbs Pre-Market On $2.4 Deal To Acquire Orna Therapeutics ↗
The acquisition will strengthen Lilly’s pipeline with a new class of therapies built on engineered circular RNA and proprietary lipid nanoparticles. 
Via Stocktwits
Dow 50,000: A Milestone for the History Books Amidst an AI Spending War ↗
Via Chartmill
Topics Artificial Intelligence Stocks
News headline image
HIMS Stock In Turmoil: Retail Bulls Bet On Rebound, Skeptics See Bloodbath After Compounded Weight-Loss Pill Halt ↗
Retail bulls pointed to similar price levels during high short interest in late 2024 and said ending compounded sales removes the risk of a costly legal fight. 
Via Stocktwits
Topics Intellectual Property Law Enforcement
News headline image
Eli Lilly Shares Surge on Weight-Loss Drug Momentum. Is It Time to Buy the Stock? ↗
It doesn't look too late to buy the stock. 
Via The Motley Fool
News headline image
Medicare Changes in 2026 Every Retiree Needs to Know: The Good, the Bad, and the Ugly ↗
Retirees should brace themselves for both positive and negative changes to Medicare this year. 
Via The Motley Fool
Topics Economy Government Retirement
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider. 
Via The Motley Fool
News headline image
3 Things Investors Need to Know About the Healthcare Sector in 2026 ↗
The most recent gold rush in weight loss drugs isn't done just yet. 
Via The Motley Fool
Topics Economy
News headline image
1 Brilliant Vanguard Index Fund to Buy Before It Soars 120%, According to a Wall Street Analyst ↗
Tom Lee says the S&P 500 (a benchmark for the U.S. stock market) can hit 15,000 by 2030. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗
Via MarketBeat
News headline image
Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition
Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83... 
Via MarketMinute
Topics Earnings Economy
News headline image
AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months
In a breakthrough that many are calling the "Penicillin Moment" of the 21st century, researchers at the Massachusetts Institute of Technology, led by bioengineering pioneer James Collins, have... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,... 
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore ↗
The market for obesity drugs may soon reach almost $100 billion. 
Via The Motley Fool
News headline image
The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market
The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
What Does the Market Think About Eli Lilly and Co? ↗
 
Via Benzinga
News headline image
Why Shares of Novo Nordisk Stock Collapsed This Week ↗
The drugmaker is facing pricing pressures on its weight loss medications. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.